<code id='7155C4142C'></code><style id='7155C4142C'></style>
    • <acronym id='7155C4142C'></acronym>
      <center id='7155C4142C'><center id='7155C4142C'><tfoot id='7155C4142C'></tfoot></center><abbr id='7155C4142C'><dir id='7155C4142C'><tfoot id='7155C4142C'></tfoot><noframes id='7155C4142C'>

    • <optgroup id='7155C4142C'><strike id='7155C4142C'><sup id='7155C4142C'></sup></strike><code id='7155C4142C'></code></optgroup>
        1. <b id='7155C4142C'><label id='7155C4142C'><select id='7155C4142C'><dt id='7155C4142C'><span id='7155C4142C'></span></dt></select></label></b><u id='7155C4142C'></u>
          <i id='7155C4142C'><strike id='7155C4142C'><tt id='7155C4142C'><pre id='7155C4142C'></pre></tt></strike></i>

          entertainment

          entertainment

          author:entertainment    Page View:3
          Thomas Massie -- health policy coverage from STAT
          Rep. Thomas Massie (R-Ky.) Kevin Dietsch/Getty Images

          WASHINGTON — House lawmakers late Tuesday voted to attach a U.S. ban on controversial infectious disease research to legislation that could ultimately fund federal health agencies like the National Institutes of Health.

          The bill would bar any federal agencies from funding so-called gain-of-function research, which involves altering a pathogen to study its spread, potentially making it more transmissible or severe in the process.

          advertisement

          The spending bill already included a restriction on funding this research in any country determined to be a “foreign adversary,” including China. Scientists at the Wuhan Institute of Virology studied gain-of-function in some viruses, fueling theories that the Covid-19 pathogen was a lab leak. Those theories have never definitively been proven.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Why Eli Lilly’s earnings didn’t quite live up to the hype
          Why Eli Lilly’s earnings didn’t quite live up to the hype

          KristofferTripplaar/APEventually,theluckiestcompaniesgettodealwithaveryparticularproblem:whattodowhe

          read more
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban
          The Supreme Court will review a ruling striking down a domestic violence federal gun ban

          WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

          read more

          Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

          DarronCummings/APEliLillysaidFridaythatitwillacquireDermira,asmallbiotechdevelopingdrugsforchronicsk